What’s in the Cards for Repros (RPRX) this Earnings Season? – Zacks.com

Posted: May 5, 2017 at 2:49 pm

Repros Therapeutics Inc. (RPRX - Free Report) is expected to report first-quarter 2017 results this month. Lets see how things are shaping up for this quarter.

Repros Therapeutics share price has decreased 28.8% year to date, while the Zacks classified Medical-Biomed/Genetics industry gained 4.7%.

Repros is a development-stage biotech company focused on the development of treatments for hormonal and reproductive system disorders. With no approved products in its portfolio yet, investors are expected to remain focused on pipeline-related updates by the company. Repros pipeline presently comprises enclomiphene and Proellex.

The most advanced candidate in Repros pipeline is enclomiphene, which is currently under review in the EU. The company intends to get the candidate approved for the treatment of secondary hypogonadism. A decision on the approval status of the candidate should be out in 2017.

Moreover, Repros is evaluating enclomiphene for the treatment of low testosterone level in overweight men. The drug was approved in the EU in 2016 for this indication while the phase II study data is under review in the U.S.

Proellex is being evaluated in phase II orally administered trials for the treatment of endometriosis and uterine fibroids under partial clinical hold with low oral dosage. Repros held a discussion with the FDA in April regarding its progress and the next steps in the development of Proellex for the treatment of uterine fibroids. As per the discussion, the FDA will continue to maintain partial clinical hold as the agency internally reviews data related to the effect of the same on the liver. Repros Therapeutics and its panel of liver experts said that they will submit additional information to the FDA and offer a proposed clinical protocol in a month. We expect update on the data at the first quarter conference call.

The company is also evaluating Proellex in a phase IIb study for uterine fibroids by vaginal delivery. However, this study has no clinical hold issues. The company presented positive topline data from this study in November last year.

Stocks that Warrant a Look

Here are some health care stocks that you may want to consider, as our model shows that they have the right combination of elements a positive Zacks Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to post an earnings beat this quarter.

You can uncover the best stocks to buy or sell before theyre reported with our Earnings ESP Filter.

Aurinia Pharmaceuticals Inc (AUPH - Free Report) has an Earnings ESP of +10% and a Zacks Rank #3. The company is expected to report on May 10. You can see the complete list of todays Zacks #1 Rank stocks here.

FibroGen, Inc (FGEN - Free Report) has an Earnings ESP of +23.81% and a Zacks Rank #3. The company is scheduled to report on May 9.

Immune Design Corp. (IMDZ - Free Report) has an Earnings ESP of +11.29% and a Zacks Rank #3. The company is expected to report on May 9.

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>

Here is the original post:
What's in the Cards for Repros (RPRX) this Earnings Season? - Zacks.com

Related Post

Comments are closed.

Archives